shares of west pharmaceutical services inc slid nearly 20 in premarket trading thursday after the maker of injectable pharmaceuticals posted thirdquarter results that missed wall streets expectations and cut its fullyear guidance the exton pa company reported adjusted earnings of 203 a share amid a 28 decline in sales to 6869 million analysts polled by factset on average were expecting an adjusted profit of 212 a share on sales of 7274 million west said it now expects fullyear adjusted earnings of 815 to 820 a share down from a prior forecast of 9 to 915 a share and sales of 283 billion to 284 billion down from prior guidance of 295 billion to 2975 billion wall street had been looking for fullyear earnings of 907 a share on sales of nearly 297 billion according to factset west shares which closed wednesday at 25440 were recently down more than 19 to 205 in premarket trading